title: Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein.
abstract: BACKGROUND
  Dihydroergotamine (DHE) and sumatriptan are contraindicated in patients with cardiovascular disease because of their vasoconstricting properties, which have originally been explored in proximal coronary arteries. Our aim was to investigate DHE and sumatriptan in the proximal and distal coronary artery, middle meningeal artery and saphenous vein.
  
  
  METHODS
  Blood vessel segments were mounted in organ baths and concentration response curves for DHE and sumatriptan were constructed.
  
  
  RESULTS
  In the proximal coronary artery, meningeal artery and saphenous vein, maximal contractions to DHE (proximal: 8 ± 4%; meningeal: 32 ± 7%; saphenous: 52 ± 11%) and sumatriptan (proximal: 17 ± 7%; meningeal: 61 ± 18%, saphenous: 37 ± 8%) were not significantly different. In the distal coronary artery, contractions to DHE (5 ± 2%) were significantly smaller than those to sumatriptan (17 ± 9%). At clinically relevant concentrations, mean contractions to DHE and sumatriptan were below 3% in proximal coronary arteries and below 6% in distal coronary arteries. Contractions in the meningeal artery and saphenous vein were higher (7%-38%).
  
  
  CONCLUSIONS
  Contractions to DHE in distal coronary arteries are smaller than those to sumatriptan, while at clinical concentrations they both induce only slight contractions. In meningeal arteries contractions to DHE and sumatriptan are significantly larger, showing their cranioselectivity. Contractions to DHE in the saphenous vein are higher than those in the arteries, confirming its venous contractile properties.
authors: Department of Internal Medicine, Division of Pharmacology, Erasmus Medical Center, The Netherlands.
authors: Sieneke
authors: S
authors: Labruijere
authors: Department of Internal Medicine, Division of Pharmacology, Erasmus Medical Center, The Netherlands.
authors: Kayi Y
authors: KY
authors: Chan
authors: Department of Internal Medicine, Division of Pharmacology, Erasmus Medical Center, The Netherlands.
authors: René
authors: R
authors: de Vries
authors: Heart Valve Bank Rotterdam, Erasmus Medical Center, The Netherlands.
authors: Antoon J
authors: AJ
authors: van den Bogaerdt
authors: Department of Neurosurgery, Erasmus Medical Center, The Netherlands.
authors: Clemens M
authors: CM
authors: Dirven
authors: Department of Internal Medicine, Division of Pharmacology, Erasmus Medical Center, The Netherlands.
authors: Ah Jan
authors: AJ
authors: Danser
authors: Autonomic Technologies Inc., USA.
authors: Shashidhar H
authors: SH
authors: Kori
authors: Department of Internal Medicine, Division of Pharmacology, Erasmus Medical Center, The Netherlands a.vanharen-maassenvandenbrink@erasmusmc.nl.
authors: Antoinette
authors: A
authors: MaassenVanDenBrink
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003331:Coronary Vessels / Q000187:drug effects*; D004087:Dihydroergotamine / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008576:Meningeal Arteries / Q000187:drug effects*; D008875:Middle Aged; D009924:Organ Culture Techniques; D012501:Saphenous Vein / Q000187:drug effects*; D018170:Sumatriptan / Q000494:pharmacology*; D014661:Vasoconstriction / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology*; D055815:Young Adult
chemical_list: D014662:Vasoconstrictor Agents; D004087:Dihydroergotamine; D018170:Sumatriptan
keywords: 5-HT; Migraine; dihydroergotamine; human coronary artery; sumatriptan; vasoconstriction